Over the past 5 years, the single best sector to invest in has been in biotech. Big pharma has been desperately seeking to grow through acquisition, using their cash hordes to buy publicly traded r&d centers. More than that, they’re buying free cash flow, executing deals that are accretive to earnings. The latest takeout, SLXP, is just one of many that have been executed in recent years.
So who’s next?
For that, I did a simple search, scouring for companies doing over $100 million in revenues, free cash flow positive, growing revenues by more than 15%. Here is the short list.
DEPO
ACOR
ANIK
CBM
EBS
ENTA
INSY
LCI
PDLI
TECH
SGNT
ACET
CRL
Within the larger pharma names, here are my favorites to get taken over next.
JAZZ
MDVN
PCYC
TARO
QGEN
UTHR
That’s it. There’s a lot of chaff out there, names without revenues and earnings, pure speculative dice rolls. But there are only a few, with market caps under $20 billion, that are still independently traded. My favorites are JAZZ and MDVN, who are cash cows trading at reasonable valuations.
Comments »
